27 results about "Brain trauma" patented technology

The invention relates to the technical field of medicine, in particular to application of an Acp5 inhibitor in cerebral edema after traumatic brain trauma, and the Acp5 inhibitor comprises a medicine with the ACP5 inhibitor as an active component and a prodrug form of the medicine. According to the invention, through an enzyme-substrate key activation mechanism, a drug is coupled by using an ACP5 specific substrate peptide, dual response release is realized in a lesion area, and the targeting property and the safety are remarkably improved. The prodrug is composed of a core inhibitor module, an ACP5 substrate peptide module and a pH response connection module, and can accurately inhibit ACP5 + macrophage infiltration and reduce encephaledema volume and neuroinflammation. The application can effectively treat acute and chronic encephaledema, reduce off-target effect and side effect, and provide a brand new treatment strategy for traumatic brain trauma.

The present invention belongs to the technical field of medicine. Disclosed are a class of magnolol / honokiol derivatives, a preparation method therefor, a pharmaceutical composition thereof and the use thereof. Specifically, disclosed in the present invention are magnolol / honokiol nitrone derivatives as represented by general formulas (I) and (II). Such derivatives are prepared by means of artificial synthesis. Further provided are a pharmaceutical composition containing same, and the use thereof against inflammation, against cerebral infarction, in the treatment of amyotrophic lateral sclerosis, and against cerebral trauma.

The invention discloses a 2-(piperidinyl) pyridazinone compound (I), pharmaceutically acceptable salts thereof, a preparation method of the 2-(piperidinyl) pyridazinone compound, a pharmaceutical composition of the 2-(piperidinyl) pyridazinone compound and application of the 2-(piperidinyl) pyridazinone compound in preparation of drugs for treating and / or preventing nervous system related diseases. Comprising but not limited to vascular dementia, Alzheimer's disease, frontotemporal dementia, Prion disease, dementia with Lewy bodies, Parkinson's disease, Huntington's disease, HIV-related dementia, multiple sclerosis, amyotrophic lateral sclerosis, neuropathic pain, cerebral arterial thrombosis, hemorrhagic stroke, nerve injury caused by cerebral trauma and other diseases;

This invention relates to the pharmaceutical field, specifically to the application of tissue inhibitor metalloproteinases-2 (TIMP2) in the preparation of drugs for the prevention or treatment of traumatic brain injury. TIMP2 protein can increase the fall latency in rotarod experiments in mice with traumatic brain injury; improve the motor balance ability of mice with traumatic brain injury on a balance beam; improve neurological function impairment in mice with traumatic brain injury; and reduce Evans blue permeability in brain tissue. In brain microvascular endothelial cells (HBMECs), TIMP2 protein can participate in maintaining the integrity of the endothelial barrier, reversing the loss of expression and altered localization of the connectome complex induced in an in vitro traumatic brain injury model, and reducing luciferase leakage. This invention also provides the application of TIMP2 protein as an Integrin α3β1 ligand in the preparation of drugs for the treatment of central nervous system diseases caused by blood-brain barrier dysfunction. TIMP2 protein exerts its function by binding to the cell membrane receptor Integrin α3β1, regulating VE-Cadherin phosphorylation. TIMP2 protein shows promising application prospects in the treatment of blood-brain barrier dysfunction caused by traumatic brain injury.

The invention discloses 2-sulfur-3-(piperidinedithio) phthalide (I), pharmaceutically acceptable salts thereof, a preparation method of the 2-sulfur-3-(piperidinedithio) phthalide (I), a pharmaceutical composition of the 2-sulfur-3-(piperidinedithio) phthalide (I) and application of the 2-sulfur-3-(piperidinedithio) phthalide (I) in preparation of drugs for treating and comprising but not limited to vascular dementia, Alzheimer's disease, frontotemporal dementia, Prion disease, dementia with Lewy bodies, Parkinson's disease, Huntington's disease, HIV-related dementia, multiple sclerosis, amyotrophic lateral sclerosis, neuropathic pain, cerebral arterial thrombosis, hemorrhagic stroke, nerve injury caused by cerebral trauma and other diseases;

This invention provides an artificial dura mater material, its preparation method, and its applications, belonging to the field of biomedical technology. Addressing the shortcomings of traditional synthetic dura mater, this invention utilizes poly(L-lactide-caprolactone) (PLCL) with a specific concentration of RAPA, processed using electrospinning. It exhibits low porosity and a dense texture, inducing rapid endothelialization of the dura mater in the early stages of traumatic brain injury. Subsequently, with the release of RAPA, the material's porosity increases, facilitating the proliferation and growth of newly formed dura mater cells. Simultaneously, RAPA can prevent excessive proliferation of new endothelial cells and scar hyperplasia. It can selectively inhibit pathological proliferation without impairing necessary lymphatic drainage; while maintaining the physical structural integrity of the dura mater, it can promote neurological function repair.

This utility model relates to the field of rehabilitation training devices, and particularly to a rehabilitation training device for promoting awakening in patients with severe traumatic brain injury and persistent coma. It includes a bed frame, with a pillow fixedly connected to the upper rear part of the bed frame. A first arm movement device is movably connected to the left rear part of the bed frame, and a second arm movement device is movably connected to the right rear part of the bed frame. This rehabilitation training device for patients with severe traumatic brain injury and persistent coma utilizes the first arm movement device. The patient's arm is placed within a first and second support plate, and the arm is restrained by straps. When a motor is activated, it drives a transmission rod to rotate, which in turn rotates a connecting block and the first support plate on its right side. This allows the first and second support plates to reciprocate at different angles, thereby enabling the patient's arm to move and facilitating awakening and rehabilitation.

The invention discloses a multi-modal fusion portable cerebral trauma first-aid navigation system and method, and relates to the technical field of cerebral trauma first-aid navigation. The system comprises a handheld navigation device, a data acquisition module, a pose resolving module, a feature extraction module and a boundary recognition module. The handheld navigation equipment integrates a miniature ultrasonic probe and a 9-axis inertial measurement unit, a data acquisition module synchronously acquires intracranial ultrasonic echo sequence data and spatial motion parameters, and a pose resolving module resolves the spatial motion parameters in real time to determine real-time spatial pose data of the equipment in a head coordinate system. The feature extraction module inputs the ultrasonic echo sequence data into a pre-trained convolutional neural network model to output a multi-scale ultrasonic feature vector, and the boundary recognition module generates hematoma boundary dynamic labeling information in combination with the multi-scale ultrasonic feature vector and the real-time spatial pose data. The system is suitable for scenes of on-site first aid, patient transfer and the like, and assists medical staff in mastering the intracranial hematoma condition.

The invention discloses amine alkoxy cotinine compounds (I), pharmaceutically acceptable salts thereof, a preparation method of the amine alkoxy cotinine compounds, a pharmaceutical composition of the amine alkoxy cotinine compounds and application of the amine alkoxy cotinine compounds in preparation of drugs for treating and / or preventing nervous system diseases. Comprising but not limited to vascular dementia, Alzheimer's disease, frontotemporal dementia, Prion disease, dementia with Lewy bodies, Parkinson's disease, Huntington's disease, HIV-related dementia, multiple sclerosis, amyotrophic lateral sclerosis, neuropathic pain, cerebral arterial thrombosis, hemorrhagic stroke, nerve injury caused by cerebral trauma and other diseases;

The invention discloses a 3-(piperidine alkyl dithioalkyl) phthalide compound (I), pharmaceutically acceptable salts thereof, a preparation method thereof, a pharmaceutical composition thereof and application of the 3-(piperidine alkyl dithioalkyl) phthalide compound in preparation of drugs for treating and / or preventing nervous system related diseases. Comprising but not limited to vascular dementia, Alzheimer's disease, frontotemporal dementia, Prion disease, dementia with Lewy bodies, Parkinson's disease, Huntington's disease, HIV-related dementia, multiple sclerosis, amyotrophic lateral sclerosis, neuropathic pain, cerebral arterial thrombosis, hemorrhagic stroke, nerve injury caused by cerebral trauma and other diseases;

A method for constructing a predictive model for the 28-day mortality risk of patients with severe traumatic brain injury (sTBI) includes: collecting clinical data of patients undergoing sTBI surgery; screening samples that meet the inclusion and exclusion criteria and grouping them according to 28-day survival; collecting clinical indicators of the samples and calculating serum sodium variability on the 8th postoperative day; screening candidate variables using LASSO regression and simplifying variables through correlation analysis and multicollinearity diagnosis; dividing the dataset into training and test sets, and determining independent predictors through univariate and multivariate logistic regression analysis; constructing a nomogram prediction model based on the independent predictors, and validating the model performance through ROC curve, calibration curve, and decision curve analysis. The predictive model of this invention uses GCS score, oxygenation index, and 8-day serum sodium variability as core indicators, exhibiting high predictive accuracy and strong clinical operability, providing a quantitative basis for prognostic assessment and clinical intervention for sTBI patients.

The present invention relates to a pharmaceutical composition comprising crisdesalazine or a salt thereof, the pharmaceutical composition having improved stability by reducing the content of a crisdesalazine-related substance and having an improved dissolution rate by improving its inherent solubility. The present invention also relates to a pharmaceutical composition comprising crisdesalazine or a salt thereof, the pharmaceutical composition comprising crisdesalazine or a salt thereof, the pharmaceutical composition comprising crisdesalazine or a salt thereof, the pharmaceutical composition comprising crisdesalazine or a salt thereof. According to the composition disclosed by the invention, the stability and the bioavailability are ensured; and therefore, in the treatment of neurodegenerative diseases (Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, Huntington's disease, epilepsy associated with free radical neurotoxicity, cerebral trauma, spinal cord injury, and the like), inflammatory diseases (gastritis, colitis, pancreatitis, arthritis, diabetic inflammation, inflammatory bowel disease, nephritis, hepatitis, arteriosclerotic inflammation, and the like), stress disorders (anxiety disorder, dyspepsia, etc. ), and the like.

This invention discloses a class of 3-substituted phthalide compounds (I) and their pharmaceutically acceptable salts, their preparation methods, pharmaceutical compositions, and their use in the preparation of drugs for the treatment and / or prevention of neurological diseases, including but not limited to vascular dementia, Alzheimer's disease, frontotemporal dementia, Prion's disease, Lewy body dementia, Parkinson's disease, Huntington's disease, HIV-related dementia, multiple sclerosis, amyotrophic lateral sclerosis, neuropathic pain, ischemic stroke, hemorrhagic stroke, and neurological damage caused by traumatic brain injury;

The invention discloses a 3-(piperidine alkyl sulfide or seleno) phthalide compound (I), pharmaceutically acceptable salts thereof, a preparation method thereof, a pharmaceutical composition and application thereof in preparation of drugs for treating and / or preventing nervous system related diseases. Comprising but not limited to vascular dementia, Alzheimer's disease, frontotemporal dementia, Prion disease, dementia with Lewy bodies, Parkinson's disease, Huntington's disease, HIV-related dementia, multiple sclerosis, amyotrophic lateral sclerosis, neuropathic pain, cerebral arterial thrombosis, hemorrhagic stroke, nerve injury caused by cerebral trauma and other diseases;

The present invention belongs to the technical field of medicine. Disclosed are a pyranocarbazole derivative and a preparation method therefor, and a pharmaceutical composition thereof and the use thereof. Specifically, disclosed in the present invention are pyranocarbazole derivatives as represented by general formulas I and II. The derivative is prepared by means of artificial synthesis. Further disclosed are a pharmaceutical composition containing the derivative, and the use thereof in resisting inflammation, resisting ischemic cerebral injury, relieving pain, resisting brain trauma, treating post-stroke depression, treating vascular dementia and cerebral small vessel disease, resisting Alzheimer's disease, and treating amyotrophic lateral sclerosis.

The present invention provides a pregnancy-specific glycoprotein (e.g., PSG1) for use in a method of treating neurological disorders or for stimulating the survival or recovery of tissue damaged by stroke or brain trauma in a subject. The PSG1 may be Fc-labeled PSG1.

Disclosed is a system for evaluating brain trauma via regional changes in tissue impedance. The present disclosure describes a system for non-invasive intracranial monitoring, comprising two or more affecting electrodes arranged between a conductive location of a cranium of a patient and a location on a scalp of the patient, two or more effected electrodes arranged between the conductive location of the cranium of the patient and the location on the scalp of the patient, and processing circuitry configured to apply an electrical stimulus between the two or more affecting electrodes, measure an electrical stimulus differential between the two or more effected electrodes, calculate, for the two or more effected electrodes, a value of an impedance metric, and identify, based on the calculated value of the impedance metric, a health condition of the patient.

The invention relates to the technical field of medical education, in particular to a multi-modal data fused craniocerebral trauma education achievement evaluation method and system. The invention discloses a multi-modal data fused craniocerebral trauma education achievement evaluation method. The method comprises the following steps of S1, performing induction association on a craniocerebral trauma cognitive module and a craniocerebral trauma cognitive node of a craniocerebral trauma cognitive map to obtain a first score weight; s2, constructing a craniocerebral trauma induction route through a craniocerebral trauma cognitive module and a craniocerebral trauma cognitive node to obtain a second score weight; s3, face language data information of participants is collected, and a third score weight is obtained through the face coding technology; and S4, setting a first threshold value, a second threshold value and a third threshold value to obtain a final score, and generating a craniocerebral trauma education achievement evaluation report. According to the method, the craniocerebral trauma educational achievement is evaluated through triple evaluation methods of module matching, induction routes and a facial language coding technology.

The invention belongs to the technical field of rehabilitation robots, and particularly relates to a power-assisted elbow and wrist exoskeleton based on a variable-rigidity actuator and a control method of the power-assisted elbow and wrist exoskeleton. According to the exoskeleton, variable rigidity actuators are integrated at elbow joints and wrist joints, and by actively adjusting the joint rigidity and driving torque, a safer and more comfortable power-assisted exercise and rehabilitation training environment conforming to physiological mechanical characteristics is provided for patients suffering from apoplexy hemiplegia, cerebral trauma and the like. In the aspect of ergonomics, the joint physiological rotation center and the human body structure characteristics are combined, and the fitting degree and comfort of exoskeleton wearing are guaranteed; in the aspect of the control method, high-precision position / torque tracking and active compliance are realized through multi-degree-of-freedom dynamic modeling and feedback linearization control; and in the aspect of safety design, a rigidity self-adaptive mechanism is built in, and inherent flexibility and man-machine co-protection safety in a collision or abnormal state can be guaranteed without depending on an external sensor assembly.

The application provides a medical brain trauma emergency treatment intelligent system, which comprises a suitcase body, the suitcase body comprises symmetrically arranged left and right box bodies, first sliding blocks and second sliding blocks are respectively arranged on side grooves in the left and right box bodies, connecting rods are connected between the two first sliding blocks and between the two second sliding blocks, two tension springs are respectively connected to two ends of a head pad, and lower ends of the left and right box bodies are hinged through hinge pieces; the left and right box bodies are respectively provided with a blind hole and a through hole, the blind hole and the through hole correspond to each other after the left and right box bodies are unfolded to a certain angle, and a fixing rod extends into the blind hole from the through hole. The fixing rod is extended into the blind hole from the through hole and then locked to avoid the left and right box bodies from approaching each other, and then the head of a patient can be placed in a first arc-shaped groove on the head pad, the tension spring is used to reduce shock during emergency transportation, and the suitcase body is convenient for medical staff to carry.

The application belongs to the technical field of biological medicine, and provides application of tyrosol sodium sulfate and derivative tyrosol compounds in preparation of brain health products. The structure of the tyrosol sodium sulfate and the derivative tyrosol compounds is shown as formula I, which can effectively reduce the infarction area after cerebral ischemia, and reduce cerebral edema caused by cerebral ischemia, and has wide application in resisting cerebral ischemia and improving cerebral edema and cerebral infarction caused by cerebral ischemia. Meanwhile, the tyrosol sodium sulfate and the derivative tyrosol compounds can effectively improve learning and memory ability, promote recovery of brain function, and have wide application in treating behavior / cognitive dysfunction diseases such as brain trauma, cerebrovascular accident, Alzheimer's disease and Parkinson's disease. Formula I.

The invention discloses 3-(piperidine alkyl sulfenyl) benzyloxy phthalide (I), pharmaceutically acceptable salts thereof, a preparation method thereof, a pharmaceutical composition thereof and application of the 3-(piperidine alkyl sulfenyl) benzyloxy phthalide (I) in preparation of drugs for treating and / or preventing nervous system related diseases. Comprising but not limited to vascular dementia, Alzheimer's disease, frontotemporal dementia, Prion disease, dementia with Lewy bodies, Parkinson's disease, Huntington's disease, HIV-related dementia, multiple sclerosis, amyotrophic lateral sclerosis, neuropathic pain, cerebral arterial thrombosis, hemorrhagic stroke, nerve injury caused by cerebral trauma and other diseases;

This invention discloses a class of piperidine alkyl dihydroxyphthalide compounds (I) and their pharmaceutically acceptable salts, their preparation methods, pharmaceutical compositions, and their use in the preparation of medicaments for treating and / or preventing diseases by means of anti-oxidative stress, inhibition of amyloid aggregation, metal ion complexation, or anti-neuroinflammatory effects, including but not limited to vascular dementia, Alzheimer's disease, frontotemporal dementia, Prion's disease, Lewy body dementia, Parkinson's disease, Huntington's disease, HIV-related dementia, multiple sclerosis, amyotrophic lateral sclerosis, neuropathic pain, ischemic stroke, hemorrhagic stroke, and neurological damage caused by traumatic brain injury;

The invention discloses an amine alkoxy nicotine compound (I), pharmaceutically acceptable salts thereof, a preparation method thereof, a pharmaceutical composition thereof and application of the amine alkoxy nicotine compound in preparation of drugs for treating and / or preventing nervous system diseases. Comprising but not limited to vascular dementia, Alzheimer's disease, frontotemporal dementia, Prion disease, dementia with Lewy bodies, Parkinson's disease, Huntington's disease, HIV-related dementia, multiple sclerosis, amyotrophic lateral sclerosis, neuropathic pain, cerebral arterial thrombosis, hemorrhagic stroke, nerve injury caused by cerebral trauma and other diseases;

The invention discloses 3-(aminoalkylthio) benzyloxy phthalide (I), pharmaceutically acceptable salts thereof, a preparation method thereof, a pharmaceutical composition thereof and application of the 3-(aminoalkylthio) benzyloxy phthalide (I) in preparation of drugs for treating and / or preventing nervous system related diseases. Comprising but not limited to vascular dementia, Alzheimer's disease, frontotemporal dementia, Prion disease, dementia with Lewy bodies, Parkinson's disease, Huntington's disease, HIV-related dementia, multiple sclerosis, amyotrophic lateral sclerosis, neuropathic pain, cerebral arterial thrombosis, hemorrhagic stroke, nerve injury caused by cerebral trauma and other diseases; .

The application discloses a kind of gold palladium-nitrogen doped carbon ribbon decorated g-C3N4 Nanosheet and its preparation method and application, UFR-NC is doped in g-C3N4 / To form g-C3N4 / UFR-NC composite nanomaterial;With g-C3N4 / UFR-NC composite nanomaterial as carrier, gold palladium shell core particle is loaded on g-C3N4 / UFR-NC composite nanomaterial to obtain gold palladium-nitrogen doped carbon ribbon decorated g-C3N4 Nanosheet.The gold palladium-nitrogen doped carbon ribbon decorated g-C3N4 Nanosheet of the application has multiple enzyme-like activities, good photocatalytic hydrogen production and hydrogen storage and release performance;At the same time, under the enhancement of 808 nm near-infrared light, it has multiple enzyme-like activities, high hydrogen storage and release performance.Oxidative stress damage in vivo can be reduced and neuroinflammation is inhibited, and in the treatment of Parkinson's disease, Alzheimer's disease, brain trauma, cerebral apoplexy and other microglia-mediated neuroinflammatory encephalopathy, there is obvious therapeutic effect.

The invention discloses an N-amine alkyl pyridone compound (I) as well as pharmaceutically acceptable salts, a preparation method and a pharmaceutical composition thereof, and application of the N-amine alkyl pyridone compound in preparation of medicines for treating and / or preventing nervous system diseases. Comprising but not limited to vascular dementia, Alzheimer's disease, frontotemporal dementia, Prion disease, dementia with Lewy bodies, Parkinson's disease, Huntington's disease, HIV-related dementia, multiple sclerosis, amyotrophic lateral sclerosis, neuropathic pain, cerebral arterial thrombosis, hemorrhagic stroke, nerve injury caused by cerebral trauma and other diseases;